FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108292279> ?p ?o ?g. }

• W2108292279 endingPage "16" @default.
• W2108292279 startingPage "1107" @default.
• W2108292279 abstract "The purpose of this study is to evaluate HER-2 and topoisomerase IIalpha (topo IIalpha) as candidates for predicting the activity of anthracyclines in the adjuvant treatment of breast cancer patients.In this study, we evaluated HER-2 and topo IIalpha gene aberrations by fluorescence in situ hybridization in a series of 430 primary breast cancer samples. Samples came from node-positive breast cancer patients randomly treated either with one of two anthracycline-based regimens [full-dose epirubicin-cyclophosphamide (HEC) and moderate-dose epirubicin-cyclophosphamide (EC)] or with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the context of a Phase III adjuvant therapy trial. Event-free survival comparisons were performed between the three study arms in the subgroups of HER-2-amplified and nonamplified tumors. An explorative analysis was also performed to evaluate the predictive value of topo IIalpha in the cohort of HER-2-amplified patients.HER-2 amplification was observed in 73 of the 354 evaluable samples (21%), whereas topo IIalpha amplification was found in 23 of the 61 evaluable HER-2-amplified tumors (38%). The three event-free survival comparisons were CMF versus HEC, CMF versus EC, and EC versus HEC. Hazard ratios (HRs) and 95% confidence intervals (CIs) were as follows: (a) CMF versus HEC, HR = 1.42 for HER-2-amplified tumors (95% CI, 0.54-3.76; P = 0.48) and 0.84 for HER-2-nonamplified tumors (95% CI, 0.49-1.44; P = 0.53); (b) CMF versus EC, HR = 1.65 for HER-2-amplified tumors (95% CI, 0.66-4.13; P = 0.29) and 0.66 for HER-2-nonamplified tumors (95% CI, 0.39-1.10; P = 0.11); and (c) EC versus HEC, HR = 0.93 for HER-2-amplified tumors (95% CI, 0.31-2.77, P = 0.90) and 1.33 for HER-2-nonamplified tumors (95% CI, 0.82-2.14; P = 0.25). Observed HRs suggest that the anthracycline-based therapy could be more effective than CMF in the subgroup of HER-2-amplified patients, whereas treatments could be equally active in the HER-2-nonamplified cohort. topo IIalpha evaluation suggests that the superiority of anthracyclines over CMF in HER-2-amplified patients could be confined to the subgroup of topo IIalpha-amplified tumors.HER-2 could have a predictive value for the activity of anthracycline-based regimens in the adjuvant therapy of breast cancer patients. The predictive value of HER-2 would most likely be related to the concomitant amplification of the topo IIalpha gene." @default.
• W2108292279 created "2016-06-24" @default.
• W2108292279 creator A5011287454 @default.
• W2108292279 creator A5011436481 @default.
• W2108292279 creator A5012531505 @default.
• W2108292279 creator A5025224681 @default.
• W2108292279 creator A5028666287 @default.
• W2108292279 creator A5036821308 @default.
• W2108292279 creator A5041495974 @default.
• W2108292279 creator A5045537345 @default.
• W2108292279 creator A5057557133 @default.
• W2108292279 creator A5068108014 @default.
• W2108292279 creator A5087380706 @default.
• W2108292279 date "2002-05-01" @default.
• W2108292279 modified "2023-10-17" @default.
• W2108292279 title "HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil." @default.
• W2108292279 cites W1262485082 @default.
• W2108292279 cites W1896390601 @default.
• W2108292279 cites W1919384911 @default.
• W2108292279 cites W1929485622 @default.
• W2108292279 cites W1976052438 @default.
• W2108292279 cites W1999582626 @default.
• W2108292279 cites W2014403549 @default.
• W2108292279 cites W2030796899 @default.
• W2108292279 cites W2031473351 @default.
• W2108292279 cites W2035332337 @default.
• W2108292279 cites W2037964145 @default.
• W2108292279 cites W2068385664 @default.
• W2108292279 cites W2089968312 @default.
• W2108292279 cites W2122872787 @default.
• W2108292279 cites W2125730396 @default.
• W2108292279 cites W2130920434 @default.
• W2108292279 cites W2131374394 @default.
• W2108292279 cites W2143668948 @default.
• W2108292279 cites W2164789874 @default.
• W2108292279 cites W2226691778 @default.
• W2108292279 cites W2231000545 @default.
• W2108292279 cites W2346648541 @default.
• W2108292279 cites W2597616474 @default.
• W2108292279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12006526" @default.
• W2108292279 hasPublicationYear "2002" @default.
• W2108292279 type Work @default.
• W2108292279 sameAs 2108292279 @default.
• W2108292279 citedByCount "71" @default.
• W2108292279 countsByYear W21082922792012 @default.
• W2108292279 countsByYear W21082922792013 @default.
• W2108292279 countsByYear W21082922792014 @default.
• W2108292279 countsByYear W21082922792015 @default.
• W2108292279 countsByYear W21082922792016 @default.
• W2108292279 countsByYear W21082922792017 @default.
• W2108292279 countsByYear W21082922792018 @default.
• W2108292279 countsByYear W21082922792019 @default.
• W2108292279 countsByYear W21082922792021 @default.
• W2108292279 countsByYear W21082922792022 @default.
• W2108292279 crossrefType "journal-article" @default.
• W2108292279 hasAuthorship W2108292279A5011287454 @default.
• W2108292279 hasAuthorship W2108292279A5011436481 @default.
• W2108292279 hasAuthorship W2108292279A5012531505 @default.
• W2108292279 hasAuthorship W2108292279A5025224681 @default.
• W2108292279 hasAuthorship W2108292279A5028666287 @default.
• W2108292279 hasAuthorship W2108292279A5036821308 @default.
• W2108292279 hasAuthorship W2108292279A5041495974 @default.
• W2108292279 hasAuthorship W2108292279A5045537345 @default.
• W2108292279 hasAuthorship W2108292279A5057557133 @default.
• W2108292279 hasAuthorship W2108292279A5068108014 @default.
• W2108292279 hasAuthorship W2108292279A5087380706 @default.
• W2108292279 hasConcept C121608353 @default.
• W2108292279 hasConcept C126322002 @default.
• W2108292279 hasConcept C143998085 @default.
• W2108292279 hasConcept C207103383 @default.
• W2108292279 hasConcept C2776694085 @default.
• W2108292279 hasConcept C2776755627 @default.
• W2108292279 hasConcept C2776802502 @default.
• W2108292279 hasConcept C2780456651 @default.
• W2108292279 hasConcept C2780835546 @default.
• W2108292279 hasConcept C2781059491 @default.
• W2108292279 hasConcept C44249647 @default.
• W2108292279 hasConcept C530470458 @default.
• W2108292279 hasConcept C71924100 @default.
• W2108292279 hasConcept C90924648 @default.
• W2108292279 hasConceptScore W2108292279C121608353 @default.
• W2108292279 hasConceptScore W2108292279C126322002 @default.
• W2108292279 hasConceptScore W2108292279C143998085 @default.
• W2108292279 hasConceptScore W2108292279C207103383 @default.
• W2108292279 hasConceptScore W2108292279C2776694085 @default.
• W2108292279 hasConceptScore W2108292279C2776755627 @default.
• W2108292279 hasConceptScore W2108292279C2776802502 @default.
• W2108292279 hasConceptScore W2108292279C2780456651 @default.
• W2108292279 hasConceptScore W2108292279C2780835546 @default.
• W2108292279 hasConceptScore W2108292279C2781059491 @default.
• W2108292279 hasConceptScore W2108292279C44249647 @default.
• W2108292279 hasConceptScore W2108292279C530470458 @default.
• W2108292279 hasConceptScore W2108292279C71924100 @default.
• W2108292279 hasConceptScore W2108292279C90924648 @default.
• W2108292279 hasIssue "5" @default.
• W2108292279 hasLocation W21082922791 @default.
• W2108292279 hasOpenAccess W2108292279 @default.
• W2108292279 hasPrimaryLocation W21082922791 @default.

• next